a profoundly reduced myocardial perfusion reserve in patients with CA, indicating microvascular dysfunction. 17 However, the link between microvascular perfusion, myocardial contractile reserve, and exercise capacity in patients with CA has not been studied. Hence, in the present study we aimed to evaluate cardiac performance in terms of myocardial work efficiency (MWE), LVGLS during exercise stress, and coronary flow velocity reserve (CFVR) in patients with CA. Furthermore, we aimed to determine the relation among exercise capacity, CFVR, and contractility.
METHODS

Patients
We prospectively enrolled 27 patients with CA (group A) and 42 healthy control subjects (group B) in the Department of Cardiology, Aarhus University Hospital, from January 2014 to November 2016. In this period, we invited all patients with CA followed or referred to our center to participate in the study. Four patients declined participation. Group A consisted of patients with wild-type transthyretin-related amyloidosis (n = 10), familial transthyretin-related amyloidosis (ATTRm) mutation carriers with cardiac involvement (n = 5), and patients with amyloid light chain (AL) amyloidosis with cardiac involvement (n = 12).
Four patients (three with AL amyloidosis, one with ATTRm) had positive results on 11 C-Pittsburgh compound B PET 18, 19 but were not subjected to endomyocardial biopsy. These patients were grouped as CA positive (group A), even though we could not rule out false-positive results on 11 C-Pittsburgh compound B PET. All individuals were $18 years of age and were included after having provided written informed consent in pursuance of the principles of the Declaration of Helsinki. The healthy control subjects and healthy mutation carriers received no medications, had no cardiopulmonary symptoms, and had normal findings on electrocardiography. The patients were included from our outpatient clinic. We excluded patients with significant valve disease or significant chronic obstructive pulmonary disorder. The local Scientific Ethics Committee of the Central Denmark Region approved the study.
Echocardiography
We used a commercially available ultrasound system (Vivid 9E; GE Vingmed Ultrasound, Horten, Norway) with a 3.5-MHz phased-array transducer (M5S).
At rest, patients underwent comprehensive echocardiographic assessment according to current guidelines. 20 At each stage of exercise, we assessed two-dimensional (2D) cine loops and tissue Doppler images from all three apical views of the left ventricle along with pulsed-wave Doppler of the mitral inflow and the left ventricular outflow tract (LVOT). Left ventricular ejection fraction (LVEF) was calculated using Simpson's biplane method of disks. Peak systolic mitral annular velocity (S 0 ) was estimated from the tissue Doppler velocity images as the average of septal, lateral, anterior, and posterior velocities. The magnitude of LVGLS 21 was obtained from frame-byframe tracking of speckle patterns throughout the left-sided myocardium in standard 2D cine loops with a frame rate > 55 frames/sec. The speckle area of interest was adjusted manually to achieve optimal tracking results. Segments with unacceptably low tracking quality were excluded. LVGLS was calculated at the time in systole when the value peaked, using a 17-myocardial segment model. 22 In this article, strain and changes in strain are reported in absolute terms.
We obtained three-dimensional (3D) left ventricular (LV) mass by sampling six heartbeats during breath-hold, aiming at a frame rate > 25 frames/sec using a 4V-D transducer. We measured both diastolic and systolic LV mass. An average of the two measurements indexed to body surface area was used as marker of amyloid burden. LV mass by 3D echocardiography has been validated in several studies showing that LV mass measured by 3D echocardiography is similar to that measured by magnetic resonance imaging. [23] [24] [25] [26] Free-wall right ventricular (RV) global longitudinal strain was assessed from a modified four-chamber view averaging the three lateral segments. Tricuspid annular systolic velocity wave (RV S 0 ) was assessed from lateral, pulsed tissue Doppler velocities. Likewise, tricuspid annular plane systolic excursion was measured from the lateral tricuspid plane. Three-dimensional RVejection fraction was obtained by sampling six heartbeats during breath-hold from a modified four-chamber view aiming at a frame rate > 25 frames/sec.
We calculated the work-pressure product as LVOT area Â velocitytime integral Â heart rate Â mean arterial blood pressure. MWE was calculated as work pressure product/3D LV mass.
For the interobserver reproducibility analysis, two observers analyzed 20 randomly selected stress echocardiograms. The same echocardiograms were used in the intraobserver repeatability analyses. The two observers were blinded to each other's analysis. We calculated the intraclass correlation coefficient and the coefficient of variation.
Data were analyzed offline using dedicated software (EchoPAC PC SW-Only version 201 [GE Healthcare, Milwaukee, WI] and TomTec 4D RV-Function [TomTec Imaging Systems, Munich, Germany]).
Assessment of CFVR
CFVR was assessed on echocardiography in a modified apical view of the distal part of the left anterior descending coronary artery using a high-frequency broadband transducer (S6-D; GE Healthcare). All subjects abstained from consuming caffeine-containing drinks for 24 hours before testing. Coronary flow velocity was obtained using color Doppler flow mapping guidance. Subsequently, a sample volume was positioned on the color signal in the artery using pulsed-wave Doppler. After baseline recording, intravenous adenosine infusion (140 mg/kg/min) was administered for $120 sec. Hyperemic flow profiles were recorded in the same angle and position as the resting recordings. In case of low increase in the flow velocity within 120 sec of adenosine challenge, infusion was continued for up to 300 sec. At least two well-defined cycles were obtained at rest and during adenosine challenge. CFVR was estimated as the ratio of hyperemic to baseline peak diastolic coronary flow velocity.
Exercise Protocol
All patients performed a multistage, symptom-limited, semisupine bicycle exercise test using the Echo Cardiac Stress Table (Lode, Groningen, the Netherlands). Workload started at 0 W and was increased by 25 W every 3 min in patients in New York Heart Association class # II and by 10 W in those in New York Heart Association class $ III. Patients were explicitly encouraged to maintain a fixed pedaling speed of 60 rounds/min and to exercise until exhaustion (Borg > 18). 27 
Statistical Methods
Normally distributed data are presented as mean 6 SD; skewed data are presented as median and interquartile range. Categorical data are presented as absolute values with percentages. Histograms and Q-Q plots were used to check continuous values for normality. Between-group differences were assessed using the t test for normally distributed data, the Mann-Whitney U test for skewed data, and the c 2 test for dichotomized data. A linear regression model was used to compare continuous variables. We calculated Pearson's coefficient of correlation for normally distributed data and Spearman's coefficient of correlation for skewed data. All tests were two-sided, and a P value < .05 was considered to indicate statistical significance. Analyses were performed using Stata/IC 13 (StataCorp, College Station, TX). Table 1 presents the clinical characteristics of the CA and control groups. Patients with CA showed a high prevalence of symptomatic heart failure. Hence, 70% of patients with CA were in New York Heart Association functional class > I, 67% received loop diuretics, 22% received angiotensin-converting enzyme inhibitors, 26% received b-blockers, and 15% received spironolactone. Furthermore, N-terminal pro-brain natriuretic peptide was significantly elevated. Interestingly, 93% of patients with CA (25 of 27) had ongoing myocardial damage with troponin T exceeding the lower normal limit of 14 ng/L. As suspected, patients with wild-type transthyretin-related amyloidosis were older and more likely to be men than those with ATTRm and AL amyloidosis.
RESULTS
Patient Characteristics
Coronary Flow Velocity Reserve
CFVR assessment was feasible in all subjects. The adenosine challenge was well tolerated in patients with CA and no significant side effects were seen.
Patients with CA had significantly higher resting coronary flow velocity (0.27 6 0.09 vs 0.18 6 0.04 m/s, P < .0001) and lower hyperemic flow velocity (0.46 6 0.17 vs 0.69 6 0.13 m/s, P < .0001) than control subjects. Subsequently, CFVR was severely reduced in patients with CA compared with control subjects (1.7 6 0.6 vs 3.9 6 0.8, P < .0001; Figure 1) . A significant correlation was seen between CFVR and troponin T in patients with CA (r = À0.48, P = .015). Furthermore, in patients with CA, strong correlations were seen between CFVR and LV mass (r = 0.43, P < .0001), between CFVR and MWE at peak exercise (r = 0.80, P < .0001), and between CFVR and LVGLS at peak exercise (r = 0.82, P < .0001).
Resting and Stress Echocardiography
Rest. As expected, LV mass was significantly higher in patients with CA than in control subjects (118 vs 77 g/m 2 , P < .0001). The LV filling pattern was significantly more restrictive in patients with CA than in control subjects, with a larger left atrial volume and a higher E/e 0 ratio ( Table 2) .
The LVEF was slightly lower in patients with CA than in control subjects. However, only 15% of patients with CA (four of 27) had a 3D LVEFs < 45%. In contrast, LV long-axis function was more uniformly affected, with lower S 0 and LVGLS magnitude. We found LVGLS > 18% in 93% of patients with CA (25 of 27). Despite the reduced long-axis function, cardiac output was comparable between the groups. However, MWE was significantly lower in patients with CA than in control subjects.
In accordance with reduced LV function, all parameters evaluating RV systolic performance were significantly reduced (3D RV ejection fraction 50% [41%-56%] vs 60% [56%-64%], tricuspid annular Data are expressed as mean 6 SD or as median (interquartile range). E-dec, E-wave deceleration time; IVRT, isovolumetric relaxation time; LA, left atrial; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; LVOT-CO, LVOT cardiac output; MAP, mean arterial blood pressure; TTP, time to peak. *Double product = heart rate Â systolic blood pressure (mm Hg/min). † Work pressure product = mean arterial blood pressure Â stroke volume Â heart rate (mm Hg $ L/min). ‡ MWE = work-pressure product/3D LV mass (mm Hg $ L/min/g). Stress. The difference in systolic performance between the groups was more pronounced at peak exercise. Hence, the magnitude of strain increased in the control group (DLVGLS 5.6 6 2.3%, P < .0001), whereas patients with CA failed to increase their LVGLS with exercise (DLVGLS 0.9 6 2.8%, P = .11; Figure 2) . In 41% of patients with CA (11 of 27), the magnitude of strain decreased with exercise. Patients with CA with decreasing strain magnitude had a higher N-terminal pro-brain natriuretic peptide (4, During exercise, only a small increase in MWE was seen in patients with CA, whereas MWE in the control group increased substantially (Figure 2 ). We found significantly lower cardiac output at peak exercise in patients with CA than in control subjects.
Intra-and interobserver variation of LVGLS and CFVR is presented in Table 3 .
Determinants of Exercise Capacity
Exercise capacity was severely reduced in patients with CA compared with control subjects (METs 5.0 6 1.6 vs 9.6 6 1.6, P < .0001). We found METs to be significantly correlated with CFVR, MWE at peak exercise, LVGLS at peak exercise, and LV mass (Figure 3) .
DISCUSSION
In the present study we evaluated the relation of CFVR and myocardial contractile reserve to exercise performance in patients with CA. We report the following main findings: (1) CFVR was severely reduced in patients with CA; (2) patients with CA had a profound lack of longitudinal myocardial deformation capacity, which is strongly related to CFVR; and (3) CFVR and deformation capacity are strongly associated with exercise capacity in patients with CA.
Coronary blood flow normally increases approximately four-to sixfold to meet increased myocardial oxygen demands. This effect is mediated by vasodilation in the arteriolar bed, which reduces vascular resistance and thereby augments flow. CFVR represents the capacity of the coronary circulation to dilate following an increase in myocardial metabolic demands. 28 Myocardial perfusion reserve has previously been evaluated in a single study of limited size, which included 21 patients with CA and used 13 N ammonia PET. 17 In that study, patients with CA had severely reduced myocardial perfusion both at rest and during hyperemic conditions. The present study confirms this finding, showing severely reduced CFVR in patients with CA. However, during resting conditions, patients with CA had elevated flow velocities. This paradox with high coronary flow velocity but low myocardial perfusion may reflect that unperfused amyloid deposits cause the LV wall thickness in these patients. Consequently, the metabolic state of the myocytes may be increased to obtain normal cardiac output. The increased flow velocity despite reduced overall myocardial perfusion may therefore be a compensatory mechanism. However, the elevated resting flow velocity may also be directly related to amyloid-induced decreased coronary artery compliance. Patients with CA were unable to obtain an increase in flow velocity during adenosine challenge. This may be explained by endothelial dysfunction induced by vascular amyloid deposits or by loss of intramural vessels due to interstitial amyloidosis. LVGLS is a marker of long-axis systolic deformation. Its magnitude is determined mainly by longitudinally oriented, subendocardially located muscle fiber contraction. LVGLS may therefore be affected by perfusion abnormalities and myocardial fibrosis. The clinical importance of LVGLS is therefore particularly high in patients with preserved LVEF. In CA, LVGLS has gained considerable clinical importance, as the majority of patients have preserved LVEF. Furthermore, the strain pattern of CA with apical sparing may be used to discriminate CA from other conditions with LV hypertrophy. In our study, patients with CA had moderately reduced LVGLS, and the difference between patients with CA and control subjects was much more pronounced at peak exercise than at lower levels of strain. The strong relation between LVGLS and CFVR demonstrated in the present study indicates that the clinical importance of LVGLS may lie in its relation to perfusion abnormality, which may play an important role in the pathogenesis of heart failure symptoms in CA. However, further studies are needed to evaluate the prognostic value of CFVR in CA.
In our study, we found a strong relation between peak exercise LVGLS and exercise capacity. Thus, the lack of physical performance in patients with CA may be related to the reduced deformation capacity. However, the reduced exercise LVGLS could also be the result of shorter exercise duration mediated by deconditioning and increased LV filling pressures. Thus, the E/e 0 ratio was also strongly related to exercise capacity. Therefore, the demonstrated relation between deformation and exercise capacity provides no certain proof that low exercise LVGLS is responsible for the low METs.
In accordance with LV performance, RV ejection fraction was slightly reduced in patients with CA, whereas RV global longitudinal strain was severely reduced. Previous studies described significantly reduced RV longitudinal function in patients with CA. In addition, it has been shown that RV strain is an independent predictor of survival. 16, 29, 30 The role of RV function during exercise should be evaluated in future studies.
Another well-known feature of CA is increased LV mass. Traditionally, 2D M-mode LV mass assessment has been used to determine the diagnosis and severity of CA. However, 2D assessment is limited by its inability to detect asymmetric LV hypertrophy. In contrast, magnetic resonance-assessed LV mass has shown high diagnostic accuracy that is superior to traditional diagnostic approaches. 31 However, magnetic resonance is time-consuming and costly and is often associated with patient discomfort due to claustrophobia and anxiety. LV mass assessment using 3D echocardiography therefore represents a simple and readily available alternative; moreover, it can be performed at the bedside and compares well with magnetic resonance. [23] [24] [25] [26] Three-dimensional LV mass can be used for MWE assessment, which reflects the myocardial ability to conduct work. However, in infiltrative disease, LV mass represents both the working myocardium and the infiltrative deposits. Therefore, MWE does not reflect the myocyte efficiency. Furthermore, this parameter has not been validated in infiltrative diseases such as CA. Therefore, there is a need for future investigations of myocardial external efficiency and myocardial oxygen consumption using acetate PET in patients with CA.
It is well known that patients with AL CA have higher mortality than those with transthyretin-related CA despite similar LVGLS impairment. This indicates that other mechanisms for LV dysfunction may be involved. 9 Even though we did not compare CFVR and stress LVGLS between CA subgroups in our study, it is possible that these parameters will offer prognostic value incremental to that of traditional myocardial performance surveillance in CA. These tests can all be performed at a single visit at the outpatient clinic and at low cost, and they cause only minimal patient discomfort. However, in the present study, we did not measure the 6-min walk distance. Therefore, future studies should investigate if CFVR and stress LVGLS provide incremental prognostic value and physical capacity insights not available from the 6-min walk distance test.
Pharmacologic treatment of CA is difficult. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers are rarely well tolerated, and their use may provoke profound hypotension. Furthermore, there is little evidence that they have any impact on survival. b-Blockers are of no proven benefit and may aggravate hypotension. Calcium channel blockers generally aggravate heart failure. Thus, loop diuretics and spironolactone are virtually the only available therapy with which to treat CA-induced heart failure.
1,2 Our finding of severely reduced CFVR indicates that future studies should focus on therapy to improve myocardial perfusion in patients with CA.
Limitations
The study reflects the experience of a single center with a relatively limited number of patients. This explains the inability to simultaneously control for several variables in the study and to define the causal relationship of the described associations. Patients with wildtype transthyretin-related amyloidosis were older and more likely to be men than those with ATTRm and AL amyloidosis. Age and sex may influence both CFVR and LV deformation capacity. Likewise, the control population differed from patients with CA with respect to age. However, age adjustment did not affect the results of the present study. The diagnostic performance of echocardiographic parameters used in the present study should be tested in a heart failure population and in patients with LV hypertrophy, as the majority of the patients in our control population were neither clinically or echocardiographically suspected for CA. In our study, no coronary angiography was performed. Therefore, some patients with CA may have had reduced CFVR due to coronary artery disease. However, no patients with CA had angina or electrocardiographic signs of ischemic heart disease. The gold standard for myocardial perfusion assessment is PET, which offers a global quantitative assessment of myocardial perfusion. In contrast, CFVR is a regional assessment and is not as reliable as PET. However, positron emission tomographic perfusion evaluation in patients with CA has shown results similar to those of the CFVR assessment in the present study. 17 We did not measure myocardial oxygen consumption in the present study, which is a limitation to the MWE results.
CONCLUSIONS
Patients with CA have a profound lack of CFVR and longitudinal myocardial deformation reserve compared with healthy control subjects. Both parameters were significantly associated with exercise capacity and may prove useful for evaluating the cardiac performance of patients with CA.
